Recently, Robak et al. showed that whole-blood PSMB5 mRNA, as well as CXCR mRNA, may have a prognostic value and could be used as independent predictors of PFS in myeloma patients [73]. This evidence concerns the gene PSMB5 and plasma cell myeloma.